Alaunos Therapeutics, Inc. annual report, FY2016

Business context and reporting period

Registrant mismatch: The supplied filing is ZIOPHARM Oncology, Inc.’s Form 10-K for the fiscal year ended December 31, 2016, filed February 16, 2017—not a filing by Alaunos Therapeutics, Inc. Verify the issuer and filing before relying on this summary. The filing covers a clinical-stage oncology company focused on immuno-oncology, engineered cell therapies and graft-versus-host disease (GvHD); it reports no product sales.

Financial results and liquidity

Revenue rose 58%, but remained small relative to operating costs; operating-loss and net-loss margins are not meaningful given the company’s lack of product revenue. The 2016 R&D increase was driven largely by a reported $126.2 million noncash charge associated with Series 1 preferred stock and dividends issued to Intrexon; underlying R&D spending also increased. The prior-year comparison included a $67.3 million noncash charge for the MD Anderson license and a $10.0 million GvHD in-process R&D charge.

Cash declined $59.7 million during 2016. Current assets were $104.9 million and current liabilities $15.8 million. Total liabilities were $58.3 million; the filing does not present a conventional debt balance as a major funding source. Series 1 preferred stock was recorded separately from liabilities, at $125.3 million, with a $127.4 million liquidation preference at year-end. The filing reports a fourth-quarter 2016 net loss applicable to common shareholders of $14.8 million, or $0.11 per share.

Material changes versus the prior period

• R&D expense increased 48% and operating loss widened by $45.2 million; G&A expense decreased 19%.
• Operating cash use increased substantially from 2015, when a large deferred-revenue inflow from the Ares collaboration supported cash flow. Cash and working capital were lower at year-end 2016.
• In June 2016, amendments reduced Intrexon’s share of product-sale net profits from 50% to 20%, subject to agreement terms and expense offsets. In exchange, ZIOPHARM issued 100,000 Series 1 preferred shares, with a $1,200 stated value per share and monthly dividends payable in additional preferred shares.
• The preferred shares’ conversion and liquidation features, and accumulating dividends, may create significant dilution or affect proceeds available to common stockholders. The filing estimated 20.5 million common shares issuable on conversion at December 31, 2016, subject to conversion terms and limits.

Outlook, commentary and risks

Management estimated that year-end cash would fund operations into the fourth quarter of 2017 and stated there were no committed additional funding sources. Management and the auditor identified substantial doubt about the company’s ability to continue as a going concern. Further financing, partnering, or reductions in development activity may be necessary; the filing warns financing could be unavailable or dilutive.

Key stated 2017 objectives included discussing a pivotal glioblastoma (GBM) trial with regulators, and planned studies in pediatric brain tumors, GBM combined with a checkpoint inhibitor, CD33 CAR-T for acute myeloid leukemia, and off-the-shelf NK cells. These are forward-looking plans, not assured guidance. The filing also described ongoing CD19 CAR-T and TCR work, including a new NCI research agreement.

Clinical findings remain preliminary and based on small studies. For the GBM Phase 1 study, the company reported interim median overall survival of 12.8 months among 17 patients at a 2016 scientific meeting, while noting follow-up and analysis were ongoing and comparisons were with historical outcomes. Reported risks include serious adverse events, cytokine release syndrome, uncertain efficacy and safety, regulatory and manufacturing challenges, intense competition, dependence on Intrexon and MD Anderson, and the need for additional capital. A reported intracranial hemorrhage death was reviewed by the trial safety committee and deemed unrelated to study drug.

Most important facts for investors to verify

• Confirm the issuer: this document is ZIOPHARM’s 2016 10-K, while the request identifies Alaunos Therapeutics.
• Assess the going-concern warning against the cash runway estimate, cash burn, development commitments and actual subsequent financing.
• Review the Series 1 preferred stock’s dividend, conversion, liquidation and protective provisions, including potential common-stock dilution.
• Check the full financial statements and notes for the nature of the $126.2 million noncash charge, deferred revenue, MD Anderson prepayments and contractual commitments.
• Validate clinical results against complete trial data, follow-up, safety disclosures and regulatory feedback; distinguish interim findings and historical comparisons from controlled evidence.
• Track whether the stated 2017 trial and development milestones were achieved and whether additional capital or partnerships were secured.